Literature DB >> 18832856

Long-term pharmacologic neuroprotection after birth asphyxia: where do we stand?

Frank van Bel1, Floris Groenendaal.   

Abstract

Perinatal hypoxia-ischemia or birth asphyxia is a serious complication with a high mortality and morbidity. For decades, neuroprotective options have been explored to reduce reperfusion and reoxygenation injury to the brain, which accounts for a substantial part of birth asphyxia-related brain damage. In this review, we focus on neuroprotective strategies with a long-term follow-up, reported in both experimental and clinical studies. Strategies related to modification of excitatory neurotransmitter production and action, reduction in free radical production and inflammation and neoneurogenesis will be briefly summarized. Since hypothermia has been proven to be beneficial for a selected group of asphyxiated neonates, we assume that a combination of this treatment option with a pharmacological means of neuroprotection will be the appropriate approach in the future. Finally, it is important to consider possible gender effects in view of the discussed pharmacological strategies. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832856     DOI: 10.1159/000143723

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  11 in total

Review 1.  Protecting motor networks during perinatal ischemia: the case for delta-opioid receptors.

Authors:  Stephen M Johnson; Sara M F Turner
Journal:  Ann N Y Acad Sci       Date:  2010-06       Impact factor: 5.691

Review 2.  Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies.

Authors:  Marcel P H van den Broek; Floris Groenendaal; Antoine C G Egberts; Carin M A Rademaker
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

3.  Astrocyte-produced carbon monoxide and the carbon monoxide donor CORM-A1 protect against cerebrovascular dysfunction caused by prolonged neonatal asphyxia.

Authors:  Helena Parfenova; Massroor Pourcyrous; Alex L Fedinec; Jianxiong Liu; Shyamali Basuroy; Charles W Leffler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-07-20       Impact factor: 4.733

4.  Treatment with docosahexaenoic acid after hypoxia-ischemia improves forepaw placing in a rat model of perinatal hypoxia-ischemia.

Authors:  Deborah R Berman; YiQing Liu; John Barks; Ellen Mozurkewich
Journal:  Am J Obstet Gynecol       Date:  2010-08-05       Impact factor: 8.661

Review 5.  Pentoxifylline in preterm neonates: a systematic review.

Authors:  Emma Harris; Sven M Schulzke; Sanjay K Patole
Journal:  Paediatr Drugs       Date:  2010-10-01       Impact factor: 3.022

6.  Oxygen glucose deprivation post-conditioning protects cortical neurons against oxygen-glucose deprivation injury: role of HSP70 and inhibition of apoptosis.

Authors:  Jian-Hua Zhao; Xian-Li Meng; Jian Zhang; Yong-Li Li; Yue-Juan Li; Zhe-Ming Fan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-02-06

7.  Hippocampal dendritic spines modifications induced by perinatal asphyxia.

Authors:  G E Saraceno; R Castilla; G E Barreto; J Gonzalez; R A Kölliker-Frers; F Capani
Journal:  Neural Plast       Date:  2012-05-07       Impact factor: 3.599

8.  Ceftriaxone attenuates hypoxic-ischemic brain injury in neonatal rats.

Authors:  Pei Chun Lai; Yen Ta Huang; Chia Chen Wu; Ching-Jung Lai; Pen Jung Wang; Ted H Chiu
Journal:  J Biomed Sci       Date:  2011-09-21       Impact factor: 8.410

9.  Current controversies in newer therapies to treat birth asphyxia.

Authors:  Pia Wintermark
Journal:  Int J Pediatr       Date:  2011-11-17

10.  Neuroprotective effects of ischemic preconditioning and postconditioning on global brain ischemia in rats through the same effect on inhibition of apoptosis.

Authors:  Zhe-Min Ding; Bing Wu; Wei-Qiao Zhang; Xiao-Jie Lu; Yu-Chang Lin; Yong-Jian Geng; Yi-Feng Miao
Journal:  Int J Mol Sci       Date:  2012-05-18       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.